A poignant example of this is the discovery of an on-target mutation in PD-L1 as a result of tumour challenge with EGFR (cetuximab) and PD-L1 (avelumab) antibodies plus chemotherapy (FOLFOX) [38]. This evidence concerns the gene CD274 and neoplasm.